The wingless/int-1 (Wnt) signal transduction pathway plays a central role in cell proliferation, survival, differentiation and apoptosis. When β-
catenin: a component of the Wnt pathway, is mutated into an active form, cell growth signaling is hyperactive and drives
oncogenesis. As β-
catenin is mutated in a wide variety of
tumors, including up to 10% of all sporadic colon
carcinomas and 20% of
hepatocellular carcinomas, it has been considered a promising target for therapeutic interventions. Therefore, we screened an in-house
natural product library for compounds that exhibited synthetic lethality towards β-
catenin mutations and isolated
nonactin, an
antibiotic mitochondrial uncoupler, as a hit compound.
Nonactin, as well as other mitochondrial uncouplers, induced apoptosis selectively in β-
catenin mutated
tumor cells. Significant
tumor regression was observed in the β-
catenin mutant HCT 116 xenograft model, but not in the β-
catenin wild type A375 xenograft model, in response to daily administration of
nonactin in vivo. Furthermore, we found that expression of an active mutant form of β-
catenin induced a decrease in the glycolysis rate. Taken together, our results demonstrate that
tumor cells with mutated β-
catenin depend on mitochondrial oxidative phosphorylation for survival. Therefore, they undergo apoptosis in response to
mitochondrial dysfunction following the addition of mitochondrial uncouplers, such as
nonactin. These results suggest that targeting mitochondria is a potential chemotherapeutic strategy for
tumor cells that harbor β-
catenin mutations.